Catalyst Brief

← Calendar

Readoutin 76d

CanSino Biologics Inc. — PCV13i

Phase 3 primary completion: A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks).

Date
Feb 2027
Type
Readout
Indication
Pneumococcal Infections

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.